HealthFounderOS™ Commercial Readiness Scan

A 4–6 week diagnostic for regenerative, longevity, and precision medicine founders

You’re 12–36 months from launch. Investors are asking for a credible commercial plan, but your team is focused (rightly) on science, trials, and regulation. The HealthFounderOS™ Commercial Readiness Scan gives you a clear, evidence-based view of how “launch-ready” you really are—and what to do next—with an AI‑first growth system built in from day one.

I’ve spent 30+ years leading launches across biologics, diagnostics, regenerative medicine, and digital health, generating 500M+ in incremental revenue and supporting exits like a 140M pharmacogenomic acquisition. Today I serve as Founder of Predictive Healthcare (PredictCare.ai) and Fractional Chief Commercial Officer for Hemostemix. I operate as an AI‑first growth operator: a hands‑on executive who uses a flexible AI stack, prebuilt and custom agents, and automations to drive concrete business outcomes—not just experiments.

This scan is how I rapidly assess, de‑risk, and prioritize your path from clinic to commercial, while designing the AI‑enabled growth engine that will power your business for the next decade.

What You Get

In 4–6 weeks, you get a concise, founder‑friendly pack you can use with your board, investors, and leadership team:

• Commercial Readiness Scorecard

  • Clear, red‑yellow‑green view across 6 pillars:
    • Indication & segment focus
    • Value narrative & differentiation
    • Evidence & RWE readiness
    • Patient & HCP insight and journeys
    • Access, pricing & payer thinking
    • Operating model, AI infrastructure, & team readiness
  • Specific risks and blind spots called out in plain language.
    

• 12–24 Month Pre‑Commercialization & Growth Blueprint (AI‑First)

  • Prioritized indications/segments and an initial positioning and value story that can inform both clinical development and BD/partner conversations.
  • A complete growth system for commercial launch that connects:
    • Marketing (demand generation, branding, education)
    • Sales (field model, key accounts, partnerships)
    • Customer service / patient support (onboarding, adherence, retention)
  • A flexible AI stack design to support that growth system, including:
    • Pre‑built agents and/or custom agents (for example, on top of agent frameworks like OpenClaw) for outreach, follow‑up, reporting, knowledge management, and internal ops.
    • Automations targeted to give founders and senior leaders 10–20 hours per week back by handling repeatable tasks across marketing, sales, customer service, and operations.
  • High‑level go‑to‑market architecture for U.S. (and ex‑U.S. if relevant): channels, partnership routes, and early thoughts on access/price corridors.
  • A pragmatic investment and sequencing view: what needs doing now, what can wait, and what you should stop worrying about.

• Early Trial Recruitment, RWE & Journey Management Opportunities

  • Recommendations for Phase 1/2 recruitment strategies (patients, investigators, sites) using digital, HCP, and advocacy channels to accelerate enrollment.
  • Concrete ideas for early RWE and patient insight programs that can:
    • Shape endpoints and refine inclusion/exclusion.
    • Strengthen your label and health‑economic story.
    • Provide real‑world proof for future launch and access discussions.
  • Design for end‑to‑end journey management across key workstreams:
    • Patient care journeys (from awareness to long‑term follow‑up).
    • HCP and site journeys (engagement, education, retention).
    • Investor relations and fundraising narratives (how your data and milestones support value creation).
  • Identification of AI agent opportunities along each journey (e.g., trial recruitment agents, patient education agents, investor update agents) to reduce manual workload and improve consistency and measurement.

• Execution Roadmap & Options

  • A simple, time‑phased roadmap (by quarter) showing how to move from your current state to AI‑first, launch‑ready.
  • Clear options: what you can do internally, what to outsource, and where an AI‑first growth operator—in the form of a fractional CCO/COO engagement—creates leverage across commercial launch, patient care workstreams, clinical trial recruitment, and investor communications.

Why Founders Use This

• De‑risk investor conversations. You show you’re thinking beyond the next trial milestone and have a structured view of how to turn science into a business—with AI as a core capability, not an afterthought.
• Avoid “too late” commercial and AI hires. You get AI‑savvy, C‑suite‑level judgment now, without prematurely building a full commercial or data team.
• Focus precious time and budget. Instead of chasing every idea, you get a ranked list of what truly matters in the next 12–24 months, with AI doing the heavy lifting wherever possible.
• Get your time back. A deliberately designed AI stack and automation layer is targeted to give founders and senior leaders 10–20 hours per week back, so they can focus on science, strategy, and capital.
• Connect every journey. Marketing, sales, customer service, patient care, clinical recruitment, and investor relations are aligned around a single story, operating system, and AI‑enabled infrastructure.

Who I Am

I’m a 54 year old executive with three decades in biopharma, diagnostics, regenerative medicine, and digital health. I’ve led 15+ U.S. and global launches, delivered 500M+ in incremental revenue, helped scale a health practice from 35M to 160M, and supported a 140M diagnostics exit. As Fractional Chief Commercial Officer for Hemostemix, I’m currently designing and activating the commercialization roadmap for a regenerative therapy—including marketing, sales, patient care workstreams, clinical trial recruitment, and an AI‑enabled operating stack.

I am an AI‑first growth operator: I use AI, agents, and automation to amplify teams, improve execution, and free leadership time, while relying on human judgment, pattern recognition, and team leadership to make the hard calls that truly drive outcomes. I’m AI‑literate, but AI‑proof where it matters most.

Let’s Talk

If you’re 12–36 months from launch—or you know investors are about to start asking tough commercial and AI questions—the HealthFounderOS™ Commercial Readiness Scan is the lowest‑friction way to get a clear, honest view of where you stand and what to do next.